Researchers at a WuXi AppTec site in Philadelphia. (Credit: WuXi)

WuXi be­came a crit­i­cal part­ner to bio­phar­ma com­pa­nies. They’re not ready if the US cracks down

It’s hard to dis­en­tan­gle WuXi AppTec’s rise from Chi­na’s. Over the last two decades, the Shang­hai-based com­pa­ny grew from noth­ing in­to a re­search su­per­store for the world’s bio­phar­ma com­pa­nies.

But as ten­sions be­tween the US and Chi­na have grown, so have doubts about WuXi’s fu­ture. It has be­come so in­ter­twined with US drug­mak­ers and biotech star­tups that it’s now seen as a risk, both by some in Con­gress and by com­pa­nies that fear get­ting caught up in a geopo­lit­i­cal strug­gle over WuXi’s al­leged ties to the Chi­nese mil­i­tary.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.